ADA, EASD Issue New Recommendations for T2DM
Additional focus on lifestyle management, self-management education and support emphasized
WEDNESDAY, Oct. 10, 2018 (HealthDay News) -- Recommendations for the management of type 2 diabetes have been updated, according to a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published online Oct. 5 in Diabetes Care.
Melanie J. Davies, M.D., from the University of Leicester in the United Kingdom, and colleagues updated previous position statements on the management of type 2 diabetes in adults, with the goals of treatment being preventing or delaying complications and maintaining quality of life.
The recommendations include additional focus on lifestyle management and diabetes self-management education and support. Efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended for those with obesity. A sodium-glucose cotransporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended for patients with clinical cardiovascular disease. An SGLT2 inhibitor with proven benefit is recommended for patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease. The first injectable medication recommended is a GLP-1 receptor agonist.
"We are proud to call for this paradigm shift as the most logical and appropriate next steps in care through this joint consensus report with EASD," William T. Cefalu, M.D., chief scientific, medical, and mission officer for the ADA, said in a statement. "The needs of our patients require that we consider the many individual life factors in order to improve quality and length of life for as many people as possible."
Several authors disclosed financial ties to pharmaceutical and medical device companies.